ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 3224

Salivary IL-1 Alpha and IL-1 Beta Levels Are Associated with Oral Mucosal Activity in Behcet’s Disease

Nilufer Alpay Kanitez1, Bahtiyar Toz1, Feyza Berktas1, Sertan Ergun2, Meltem Koray2, Nuray Gurel Polat3, Burak Erer1 and Ahmet Gül1, 1Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, 2Department of Oral Medicine, Istanbul University, Faculty of Dentistry, Istanbul, Turkey, 3Department of Microbiology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Behcet's syndrome, biomarkers and inflammation, Disease Activity, IL-1

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 10, 2015

Title: Vasculitis IV

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Recurrent oral aphthous ulcers are the common manifestation of the Behçet’s disease (BD), and they are indistinguishable from ulcers of recurrent aphthous stomatitis (RAS). There is no reliable biomarker reflecting disease activity in BD, and systemic acute phase reactants are not helpful in evaluation of active disease, especially in patients with predominantly mucocutaneous activity. We aimed to assess the potential of salivary interleukin-1 alpha and beta (IL-1α and IL-1β) concentrations as well as two S100 proteins, namely S100A12 (calprotectin) and S100A13 in comparison to their serum levels in BD, RAS, and healthy controls.

Methods: A total of 67 patients with BD, 43 patients with RAS, and 22 healthy controls with no history of aphthous ulcers or other oral mucosal disorders (NA) comprised the study group. BD patients fulfilled the ISG criteria for the diagnosis, and patients with active systemic disease were excluded. Patients with BD and RAS were classified as active and inactive according to the presence or absence of aphthous ulcers at the time of sample collection. Unstimulated saliva and serum samples were collected after overnight fasting. IL-1α, IL-1β, S100A13 and calprotectin levels were measured by ELISA, and concomitant measurements of ESR and serum CRP levels of BD patients were recorded.

Results: At the time of sample collection, 38 BD patients (18 male, mean age: 39,1±10,3) were classified as active and 29 patients (18 male, mean age: 38,9±10,5) as inactive. Similarly, 19 patients with RAS (11 male, mean age: 36,6±8,7) were active and 24 patients (7 male, mean age: 36,7±10,1) were inactive state. Mean values of salivary and serum ELISA measurements are given in Table 1. Salivary IL-1α and IL-1β, levels were higher in BD patients compared to RAS and NA even during inactive state (IL-1α p<0.001 for RAS and p<0.001 for NA, IL-1β p<0.001 for RAS and p=0.003 for NA). There was a correlation between IL-1α and IL-1β levels, but IL-1α increase was more prominent in active BD patients. No correlation was detected between salivary IL-1α and S100A13 levels. Serum CRP and ESR were within normal range in BD patients, and they showed no correlation with salivary measurements.

                    SALIVA                                                       SERUM

IL-1α

(pg/ml)

IL-1β

(pg/ml)

S100A12

(ng/ml)

S100A13

(ng/ml)

IL-1α

(pg/ml)

IL-1β

(pg/ml)

S100A12

(ng/ml)

S100A13

(ng/ml)

BD active (n=38)

2147

5.1

49.1

1.8

13.9

17.8

57.7

0.6

BD inactive (n=29)

1492

4.7

48.4

1.5

12.4

18.3

67.1

0.9

RAS active (n=19)

1324

2.3

60.1

1.8

35.2

22.8

110.0

1.9

RAS inactive (n=24)

282

0.7

37.0

1.9

28.5

23.2

146.0

1.7

Healthy controls (n=22)

361

1.8

30.3

1.3

31.4

23.3

188.0

1.2

Conclusion: These results suggest a role for IL-1α and IL-1β in the development of oral aphthous ulcers. S100A13 is known to be involved in controlled secretion of IL-1α. Increased IL-1a levels without an increase in S100A13 levels may suggest that pyroptosis or other causes of cellular damage is the main source of salivary IL-1α. Further studies are necessary both to improve saliva collection and analysis methods and to search the biomarker potential of salivary IL-1α and IL-1β concentrations in the management of mucocutaneous and systemic manifestations of BD.


Disclosure: N. Alpay Kanitez, None; B. Toz, None; F. Berktas, None; S. Ergun, None; M. Koray, None; N. Gurel Polat, None; B. Erer, None; A. Gül, None.

To cite this abstract in AMA style:

Alpay Kanitez N, Toz B, Berktas F, Ergun S, Koray M, Gurel Polat N, Erer B, Gül A. Salivary IL-1 Alpha and IL-1 Beta Levels Are Associated with Oral Mucosal Activity in Behcet’s Disease [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/salivary-il-1-alpha-and-il-1-beta-levels-are-associated-with-oral-mucosal-activity-in-behcets-disease/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/salivary-il-1-alpha-and-il-1-beta-levels-are-associated-with-oral-mucosal-activity-in-behcets-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology